Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Reprogramming RNA processing
to address underlying
drivers of disease

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Precision therapeutics for
genetically-defined dry AMD
(NASDAQ: GMTX) Jan 2021

Novel therapeutics
targeting
diseases of aging

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Leading the
next frontier in
RNA therapeutics

Building
the future of
gene therapy

Novel therapeutics
for severe
respiratory diseases

Bispecific antibodies
to improve the treatment
of serious diseases

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

New class of
regulated cell and
gene therapies

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Applying new insights in
hepcidin biology to
treat hematologic diseases

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Harnessing the power of microglia
to transform treatments for
neurodegenerative diseases

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Next generation ocular gene
therapies for vision restoration
and vision preservation

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Broadening the reach and
impact of precision medicine
to more people with cancer

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Precision therapeutics
for genetically defined
diseases

Developing first-in-class
medicines for medical conditions
prevalent in older adults

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

Harnessing the immune system
to defeat cancer with
tumor-selective immunotherapies

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020

Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)

Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.

ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Breakthrough computer-aided
drug design
for transformative medicines

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Engineered
B cells
as medicines

Discovering new medicines
for severe
neurodegenerative diseases

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways